3529:TPEXeMemory Technology, Inc. Analysis
Data as of 2026-05-28 - not real-time
¥1,040.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Atsugi Co., Ltd. is trading at ¥1,040, well below its 52‑week high and near the midpoint of its technical support (¥956) and resistance (¥1,161) levels. The RSI sits at roughly 49, indicating a neutral momentum, while the MACD histogram is firmly negative and the signal line is labeled bearish, suggesting short‑term downside pressure. Volume trends are decreasing, which compounds the liquidity concern for a stock with a market cap of ¥16.7 bn. Fundamentally, the company posted a larger FY loss than the prior year (loss widening to ¥1.14 bn) and continues to generate negative operating and free cash flow, with operating margins in the negative‑5% range. Despite these earnings challenges, the price‑to‑book ratio is only 0.52 and the price‑to‑sales is under 0.8, implying the stock is priced cheaply relative to its balance sheet. However, high 30‑day volatility (≈52%) and a beta below 0.6 highlight a volatile yet relatively insulated price profile within the consumer cyclical apparel sector.
Given the blend of technical weakness, deteriorating profitability, and modest valuation discounts, the near‑term outlook leans toward further price correction unless a clear turnaround in cash generation emerges. The low beta and undervalued book value provide some defensive attributes, but the absence of dividends and a thin analyst coverage base limit upside catalysts. Investors should weigh the risk of continued earnings erosion against the potential for a value‑oriented rebound if management can restore margins and cash flow.
Given the blend of technical weakness, deteriorating profitability, and modest valuation discounts, the near‑term outlook leans toward further price correction unless a clear turnaround in cash generation emerges. The low beta and undervalued book value provide some defensive attributes, but the absence of dividends and a thin analyst coverage base limit upside catalysts. Investors should weigh the risk of continued earnings erosion against the potential for a value‑oriented rebound if management can restore margins and cash flow.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish MACD and negative histogram
- Decreasing trading volume
- Widening fiscal loss and negative cash flow
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential price bounce toward resistance at ¥1,161
- Low beta offering relative stability
- Significant valuation discount (PB 0.52) despite earnings weakness
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Need for operational turnaround to achieve positive margins
- High volatility and exposure to consumer cyclical demand
- Undervalued balance sheet but persistent cash flow deficits
Key Metrics & Analysis
Financial Health
Revenue Growth-4.10%
Profit Margin-5.30%
ROE-3.57%
ROA-1.58%
Debt/Equity1.44
P/B Ratio0.5
Op. Cash Flow¥-388000000
Free Cash Flow¥-2250625024
Technical Analysis
TrendNeutral
RSI48.8
Support¥956.00
Resistance¥1,161.00
MA 20¥1,066.55
MA 50¥1,028.40
MA 200¥1,121.75
MACDBearish
VolumeDecreasing
Fear & Greed Index92.34
Valuation
GradeUndervalued
TypeValue
Risk Assessment
Beta0.59
Volatility51.64%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.